Health & Medicine

STAT+: Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B

23 sec read34 views0 listens

French pharmaceutical company Servier acquired Day One Biopharmaceuticals for $2.5 billion, primarily for its approved pediatric brain cancer drug Ojemda, expanding Servier's portfolio in rare cancers. This acquisition underscores the high value placed on innovative treatments for childhood diseases and signals a significant investment in pediatric oncology research and development.

Read the full article at STAT News

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

You Might Like

Cybersecurity2 days ago27 sec read

Canadian supercomputers are transforming drug discovery: Can they deliver medicines faster?

Researchers at Simon Fraser University have developed an AI framework called CGFlow, which accelerates the design of drug molecules by ensuring they can be synthesized in a laboratory. This advancement is crucial for reducing the time and cost associ...

Ali Nemati

Biotech & Pharma2 days ago24 sec read

Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development

Centrix Pharma Solutions and the University of Sussex have launched a Knowledge Transfer Partnership funded by Innovate UK to develop data-driven tools for pharmaceutical product development. This collaboration aims to integrate advanced analytics wi...

Ali Nemati

Biotech & PharmaAug 1729 sec read

Human Cell Atlas at 10: A Decade of Discovery and the Road to HCA 2.0

The Human Cell Atlas (HCA) celebrated its 10-year anniversary, marking significant advancements in single-cell and spatial data generation for tissue and organ systems. The project is now transitioning to HCA 2.0, focusing on scaling spatial atlases,...

Ali Nemati